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Abstract: This article proposes a number of recommendations for the treatment of generalized 
social phobia, based on a systematic literature review and meta-analysis. An optimal treatment 
regimen would include a combination of medication and psychotherapy, along with an assertive 
clinical management program. For medications, selective serotonin reuptake inhibitors and dual 
serotonin-norepinephrine reuptake inhibitors are first-line choices based on their efficacy and 
tolerability profiles. The nonselective monoamine oxidase inhibitor, phenelzine, may be more 
potent than these two drug classes, but because of its food and drug interaction liabilities, its 
use should be restricted to patients not responding to selective serotonin reuptake inhibitors or 
serotonin-norepinephrine reuptake inhibitors. There are other medication classes with demon-
strated efficacy in social phobia (benzodiazepines, antipsychotics, alpha-2-delta ligands), but due 
to limited published clinical trial data and the potential for dependence and withdrawal issues 
with benzodiazepines, it is unclear how best to incorporate these drugs into treatment regimens. 
There are very few clinical trials on the use of combined medications. Cognitive behavior 
therapy appears to be more effective than other evidence-based psychological techniques, and 
its effects appear to be more enduring than those of pharmacotherapy. There is some evidence, 
albeit limited to certain drug classes, that the combination of medication and cognitive behavior 
therapy may be more effective than either strategy used alone. Generalized social phobia is a 
chronic disorder, and many patients will require long-term support and treatment.
Keywords: social phobia, social anxiety disorder, psychotherapy, cognitive behavior therapy, 
antidepressant
Introduction
Social phobia (also known as social anxiety disorder) is an anxiety disorder in which 
there is a “marked and persistent fear of social or performance situations in which 
embarrassment may occur”.1 It was first included in the third edition of the Diagnostic 
and Statistical Manual of Mental Disorders (DSM) in 19802 and is included in the sec-
tion on anxiety disorders. DSM has the specifier of “generalized” relating to when fears 
are related to most social situations. By exclusion, the unspecified “nongeneralized” 
form relates to specific situations, and in the literature is often referred to as “nonge-
neralized social phobia”. For the remainder of this article, we have chosen to focus on 
generalized social phobia (hereafter simply referred to as social phobia). Generalized 
social phobia is the more relevant disorder to general psychiatric clinical work.
Social phobia has an early onset, with the median age of onset in the National 
Comorbidity Survey of 16 years.3 The most commonly reported fears relate to public 
speaking or speaking up in a meeting or a class.4 The disorder is associated with 
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  significant disability. Patients with social phobia are more 
likely to utilize medical outpatient clinics, receive lower 
incomes, be less likely to earn college degrees, or attain 
managerial, technical, or professional occupations3,5,6 than 
people not suffering with social phobia. They are also more 
impaired in family relationships, romantic relationships, 
and desire to live, with 21.9% having attempted suicide.6,7 
The course of social phobia tends to be chronic, with a long 
duration of illness8 and low rates of recovery.9
Social phobia has a high degree of comorbidity with other 
psychiatric disorders. Eighty-one percent of people suffer-
ing from social phobia reported at least one other lifetime 
DSM-IIIR disorder in the National Comorbidity Survey.3 
The odds ratio (OR) of having a second anxiety disorder is 
increased (range 7.1–8.7).3 Between 16.6%10 and 35.8%6 of 
sufferers experience major depressive disorder, with social 
phobia preceding the onset of major depressive disorder by 
12 years.6 Rates of concurrent alcohol dependence are 27.3%, 
and concurrent alcohol abuse occurs in 11.3%6 to 20.9%10 of 
patients with social phobia. For patients with social phobia 
and a comorbid alcohol misuse disorder, almost 80% devel-
oped social phobia before the alcohol misuse disorder.11 This 
seems to be the pattern with other comorbid conditions, with 
social phobia being the primary disorder in 71.4%.3,6 Patients 
who have social phobia and a comorbid alcohol disorder 
have an increased rate of comorbid psychiatric disorders, 
with 97% having at least one additional Axis I disorder, and 
71.7% having a personality disorder.11
Recent data from the cross-sectional World Mental Health 
surveys12 provide cross-national comparisons of social phobia 
diagnosed by DSM-IV Composite International Diagnostic 
Interview in the general populations of developed and devel-
oping countries. These data show great variation in 12-month 
prevalence. Rates are lowest in China and Japan (0.3% and 
0.5%, respectively), range from 0.6% to 1.4% in European 
countries, and are somewhat higher in the Ukraine (1.5%), 
South Africa (1.9%), Mexico (1.9%), and Colombia (2.8%). 
Rates then jump to 5.1% in New Zealand and 6.8% in the US. 
Explanations for these differences are likely to include both 
substantive and methodological reasons. The World Mental 
Health survey data indicate that social phobia has one of the 
earliest ages of onset amongst the mental disorders and yet 
is also one of the most undertreated anxiety disorders. Data 
from the New Zealand survey, the largest of the World Mental 
Health collaborating surveys, show that fewer than 5% of 
those meeting the criteria for social phobia sought treatment 
in the year of onset, and only 36% of those with a lifetime 
diagnosis of social phobia sought treatment from a health 
professional at some stage.12 This latter statistic compares 
with 57% for generalized anxiety disorder, 63% for panic 
disorder, 54% for agoraphobia, and 50% for post-traumatic 
stress disorder.
There are a number of treatment options for social 
phobia, including medication, psychotherapy, and their 
  combination. Although there have been a number of reviews 
of medications,13,14 psychological treatment,15,16 and   combined 
treatments17,18 for social phobia, and the   development of 
  clinical guidelines,18 there has been no synthesis of these data 
to identify characteristics for optimal overall   management 
of social phobia. Patients with social phobia are difficult 
to engage with psychiatric services, and to date there are 
no published data to identify how to improve treatment 
  engagement or adherence. The objective of this systematic 
review and meta-analysis was to identify optimal treatments 
for social phobia, based on a systematic review of published 
clinical trial data.
Methods
Meta-analysis of treatment trials
We performed a systematic review and meta-analysis of 
clinical trials using drugs, psychotherapy, or their combina-
tion, in social phobia. For the drug trials, the search methods 
were intended to identify all randomized, double-blind, 
parallel-group treatment trials in social phobia. For the 
psychological treatment trials, the search aimed to identify 
all randomized controlled trials (RCT). The search included 
published and unpublished studies, electronic database 
searches, searches of clinical and pharmaceutical trial 
registers, and personal communication with study authors. 
Studies were identified and obtained between September 
2011 and January 2012 using electronic databases (Embase 
[1974 to the   present] and Medline [1950 to the present]); 
reference lists of identified articles and other electronic 
search tools; clinical trials websites (http://www.clinical-
studyresults.org, http://clinicaltrials.gov, http://apps.who.int/
trialsearch/); and, when required, communication with study 
authors. The following Boolean phrases were used when 
searching electronic databases and other electronic search 
engines: “randomized controlled trial”, “treatment”, “drug”, 
“psychotherapy”, “psychological treatment”, “cognitive 
behavior therapy”, “cognitive therapy”, “exposure therapy”, 
“social phobia”, and “social anxiety disorder”.
inclusion criteria
We sought to identify RCT, either placebo-controlled or active-
controlled. Only publications in English were considered. 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
204
Canton et alNeuropsychiatric Disease and Treatment 2012:8
Studies that did not include information on treatment out-
come were excluded. Study participants were adults who were 
diagnosed with DSM-III, DSM-III-R, or DSM-IV criteria for 
social phobia/social anxiety disorder. Data from maintenance 
or discontinuation phases were not collected. We did not 
include trials of exploratory agents, eg, neurokinin-1 antago-
nists or d-cycloserine, in this review. The relevance of identi-
fied papers was initially screened using title and abstract. Full 
manuscripts of studies of interest were screened according to 
inclusion criteria. Social phobia treatment studies involving 
medications generally include a range of clinician-rated and 
patient-rated outcome measures. For this analysis, we chose 
one endpoint, ie, the proportion of responders based on clini-
cian assessments. In most studies, a responder was defined as 
someone who achieved a score of 1 or 2 on the seven-point 
Clinical Global Impression of Change (CGI) scale.19 This 
represents a rating of score of very much or much improved 
(score of 1 or 2, respectively). In four studies, response was 
defined as a 50% reduction in a clinician-rated instrument 
(eg, Liebowitz Social Anxiety Scale107 or Hamilton Anxi-
ety Scale108) or, in one case, a self-rated instrument (Fear 
Questionnaire)109. Previous meta-analyses have shown that 
changes in the CGI are broadly similar to changes in other 
clinician-rated and patient-rated instruments.20,21 The majority 
of comparative psychotherapy trials do not report responder 
rates, so a narrative review is provided.
Data synthesis and analysis
All analyses were performed using Review Manager 
  (RevMan) 5.0 (Cochrane Collaboration, 2008; http://www.
cc-ims.net/RevMan). For rates of treatment response, Mantel-
Haenszel OR were calculated using a random effects model. 
The I2 statistic was used to assess heterogeneity.
Results
Study identification and selection
The search strategy identified 410 papers. Based on a review 
of study title and abstract, 183 were selected for detailed 
review. Reasons for noninclusion included ineligible study 
design (eg, nonblinded dosing, continuation treatment 
trial, crossover trial), response data not provided in results, 
duplicate data presentation, and review articles. Ultimately, 
41 papers were selected for inclusion in the meta-analysis.
Antidepressant drugs
Selective serotonin reuptake inhibitors
This class of drugs is the most extensively tested in 
patients with social phobia, with 17 placebo-controlled 
acute treatment RCT reported. Almost half of the 
studies studied paroxetine,22–29 with 2–3 studies each for 
escitalopram,26,30 fluoxetine,31–33 fluvoxamine,34–36 and 
sertraline.37–39 The pooled OR for response to each selec-
tive serotonin reuptake inhibitor (SSRI) ranges between 
1.98 for fluoxetine and 3.41 for paroxetine (Figure 1). 
With one exception, SSRIs had significantly greater CGI 
response rates compared with p  lacebo. The single negative 
study (fluoxetine)32 was of adequate duration and used a 
high fluoxetine dose (60 mg/day), but was relatively small 
in size (n = 30 per arm), and may thus have been under-
powered to show a difference from placebo. There was 
significant heterogeneity associated with one study,29 but 
its exclusion in a sensitivity analysis had little effect on 
the pooled OR for paroxetine studies (3.43 decreased to 
3.09). In general, SSRIs showed separation from placebo 
by weeks 4–6 on a number of response or other outcome 
measures, however SSRI-placebo differences tended to 
increase out to 12 weeks of treatment. There have been 
four studies assessing the effect of continuation treatment 
with SSRIs in patients who have responded to acute treat-
ment.40–43 In these relapse prevention studies, patients were 
randomized to remain on their SSRI or were switched to 
placebo, under double-blind conditions. All four studies 
showed robust effects of the SSRIs in preventing relapse 
of social phobia (pooled OR 0.25, 95% confidence interval 
[CI] 0.18–0.35).44
Serotonin and norepinephrine reuptake inhibitors
Venlafaxine is the only serotonin-norepinephrine reuptake 
inhibitor (SNRI) studied in RCT in patients with social 
phobia, but improvements in social phobia symptom 
ratings have also been shown in an open-label trial of the 
SNRI, duloxetine.45 All five reported studies23,28,46–48 have 
shown significantly greater response rates for venlafaxine 
compared with placebo (Figure 2, OR range for treatment 
response 1.89–3.78). Four of five studies used flexible 
dosing, with mean daily doses of approximately 200 mg/day. 
The single fixed-dose comparison study46 showed no 
differences in outcome measures between 75 mg/day 
and 150–225 mg/day dose arms, and both separated from 
placebo. The onset of response across all trials was evident 
at 4–6 weeks, although maximum separation from placebo 
continued out to 12 weeks.
Monoamine oxidase inhibitors
The first placebo-controlled RCT in social phobia assessed 
phenelzine, an irreversible monoamine oxidase inhibitor. 
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Figure 1 Odds ratios and 95% Ci for treatment response in randomized placebo-controlled trials for SSRi.
Response based on CGi for all studies except for Liebowitz Social Anxiety Scale107 in van vliet et al.34 Only the highest ESC dose included for Lader et al.26
Abbreviations:  CI,  confidence  interval;  PAR,  paroxetine;  SERT,  sertraline;  ESC,  escitalopram;  FLX,  fluoxetine;  FLV,  fluvoxamine;  CGI,  Clinical  Global  Impression;   
SSRI, selective serotonin reuptake inhibitor; M-H, Mantel-Haenszel odds ratio.
The rationale for using monoamine oxidase inhibitors was 
because social phobia and atypical depression share the symptom 
of increased interpersonal sensitivity, and atypical depression is 
preferentially responsive to monoamine oxidase inhibitors.49 All 
four studies with this drug50–53 showed a significantly greater 
treatment response compared with placebo; however the 
pooled OR is heavily influenced by the results from one study50 
 ( Figure 3, upper panel). Exclusion of this study50 in a sensitivity 
analysis reduced the pooled OR from 7.22 to 4.58. There have 
also been positive open-label studies with tranylcypromine.54 
Reversible selective inhibitors of monoamine oxidase A were 
developed with the intention of reducing safety concerns due 
to drug and food interactions with the original nonselective 
irreversible monoamine oxidase inhibitors.55 RCT have been 
reported for brofaromine,56–58 a drug that was never submitted 
for regulatory approval, and moclobemide,50,59–63 which has 
been approved in many countries. Excluding brofaromine 
  trials, the pooled OR for response to moclobemide is relatively 
modest compared with other antidepressant drugs (1.95; 95% 
CI 1.37–2.79). High heterogeneity (I2 = 69%) was noted in 
the analysis of this drug class. Exclusion of three studies of 
reversible selective inhibitors of monoamine oxidase A (two 
brofaromine,56,58 one moclobemide50) reduced the heterogeneity 
to 0%, but also reduced the pooled OR from 2.96 to 1.88.
Other antidepressants
There are open-label trials in social phobia with the tricyclic 
antidepressants, imipramine64 and clomipramine,65 but no RCT. 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
206
Canton et alNeuropsychiatric Disease and Treatment 2012:8
Study
Irreversible MAOIs
Gelernter 199153 9
20
16
22
67
13
31
29
26
99
3
11
6
4
24
15 9.00 [1.60, 50.69]
7.22 [2.90, 17.97]
30.25 [6.71, 136.47]
4.51 [1.41, 14.43]
3.64 [1.30, 10.21] 33
28
26
102
18.3%
31.6%
28.5%
21.7%
100.0%
Heimberg 199852
Liebowitz 199251
Versiani 199250
Total (95% Cl)
Total events
Fahlen 199558(B) 28
90
25
69
663 659
335 213
36
193
50
84
9
65
10
57
39 11.67 [3.95, 34.45]
2.96 [1.78, 4.91]
2.26 [1.10, 4.64]
1.23 [0.35, 4.28]
1.36 [0.39, 4.72]
1.75 [1.15, 2.68]
74.11 [3.61, 1522.44]
10.39 [2.73, 39.56]
4.20 [1.73, 10.17]
1.73 [1.15, 2.62] 194
52
85
10.4%
17.4%
12.3%
14.1%
72 76 27 8.9%
69 40 53 7 9.0%
81 188 57 189 17.2%
11 15 01 4 2.5%
17 26 42 6 8.3%
100.0%
Katschnig 199763 (M)
Lott 199757 (B)
Versiani 199250 (M)
van Vliet 199256 (B)
Stein 200259 (M)
Schneier 199860 (M)
Oosterbaan 200161 (M)
Noyes 199762 (M)
Total (95% Cl)
Total events
RIMAs
Placebo Odds ratio
Weight M-H, random,  95% Cl M-H, random,  95% Cl
Odds ratio MAOIs
Response Total Response Total
0.1 0.2
Favors placebo Favors active
0.5 12 51 0
Figure 3 Odds ratios and 95% Ci for treatment response in randomized placebo-controlled trials for irreversible and reversible MAOis.
Response based on CGi for all studies except social phobia subscale of the Fear Questionnaire108 for Gelernter et al,53 and the Hamilton Anxiety Scale109 for van vliet et al.56
Abbreviations: B, brofaromine; M, moclobemide; MAOIs, monoamine oxidase inhibitors; CI, confidence interval; M-H, Mantel-Haenszel odds ratio.
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Figure 2 Odds ratios and 95% Ci for treatment response in randomized placebo-controlled trials for the serotonin-norepinephrine reuptake inhibitor, venlafaxine.
Response based on CGi for all studies.
Abbreviations: CI, confidence interval; CGI, Clinical Global Impression; M-H, Mantel-Haenszel odds ratio; SNRIs, selective norepinephrine reuptake inhibitors.
Response to atomoxetine, a selective norepinephrine reuptake 
inhibitor, was not different from placebo.66 Two place-
bo-controlled RCT in social phobia have been reported for 
mirtazapine, an antagonist at 5HT2, 5HT3, and alpha2 adreno-
ceptors. One study showed a greater reduction in relevant out-
come scales compared with placebo,67 whereas the other showed 
no difference.68 Both studies were relatively small (n = 30–33 
per treatment arm), and both studies are likely to have been 
underpowered   statistically. Nefazodone, an antagonist at 5HT1a 
and 5TH2a receptors, did not separate from placebo in a single 
large clinical trial.69 The generally negative findings in social 
phobia with receptor antagonist antidepressants contrast with 
the robust positive findings for SSRIs and SNRIs.
Antiepileptic drugs
The use of antiepileptic drugs in social phobia has been 
extensively reviewed recently.70 Only three antiepileptic 
drugs have been tested in RCT, and show distinct differences 
in efficacy. Gabapentin and pregabalin are both ligands at 
the alpha-2 delta site on voltage-gated calcium channels. 
Functionally, both drugs reduce the release of a range of 
excitatory neurotransmitters through binding to this site.71 
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There are three positive RCT with alpha-2 delta ligands72–74 
(see Figure 4). The onset of anxiolytic effects is relatively 
rapid, occurring within the first week of treatment. The 
anxiolytic dose-response has only been formally assessed 
for pregabalin, and efficacy is only evident at the maximum 
dose (600 mg/day), but not at lower doses.73,74 This is in con-
trast with the effect of pregabalin in, eg, generalized anxiety 
disorder, where the anxiolytic dose-response is seen at much 
lower doses (150 mg/day).75 There are no long-term treatment 
or relapse prevention data for alpha-2 delta ligands.
The only other antiepileptic drug assessed in RCT is 
levetiracetam, which has a complex pharmacology.70 A large 
trial against placebo was negative.76 The dose achieved in 
this trial (1180 mg/day) was at the low end of the dose range 
for epilepsy (1000–3000 mg/day). However, an earlier small 
RCT, in which higher levetiracetam doses were achieved, 
was also negative.31
Open-label trials of valproate,77 topiramate,78 and tiagabine79 
have also been reported, all of which showed reductions in 
relevant social phobia rating scales. All studies were small 
(involving 17–54 subjects), and the magnitude of the change 
in symptom ratings was within the range that has been 
reported for placebo arms in other RCT.
Benzodiazepines
In clinical practice, there appears to be widespread use of ben-
zodiazepines alone or in combination with antidepressants for 
social phobia,80,81 but clinical evidence to support this use is 
relatively limited. There are three placebo-controlled RCT, 
one each for clonazepam,82 bromazepam,83 and alprazolam.53 
All studies showed significantly greater improvement on a 
range of clinician-rating and self-rating scales compared with 
placebo. The mean doses used in these studies were generally 
modest (clonazepam 2.4 mg/day, bromazepam 21 mg/day, 
alprazolam 4.2 mg/day). The time course of response was 
only reported for the clonazepam study. Although there was 
a higher proportion of responders after one week of treat-
ment (clonazepam 13.5%, placebo 0%), maximal response 
rates were noted after 6 weeks of treatment. Continuation 
of clonazepam treatment in treatment responders has been 
shown to decrease rates of relapse in social phobia compared 
with those switched to placebo.84
Although the clinical practice of combining antidepres-
sants and benzodiazepines appears to be common, it has been 
studied in only one small RCT. Combined paroxetine and 
clonazepam had a higher response rate (albeit not a statisti-
cally significant one) in an RCT in social phobia (79% versus 
43%, P = 0.06) compared with paroxetine plus placebo.85
Antipsychotics
Increased use of second-generation antipsychotic drugs for 
anxiety disorders has been identified in US prescribing data 
between 1996 and 2007.86 The evidence base to support use 
in social phobia is very limited, with two small RCT. CGI 
response rates were not statistically significantly different 
between placebo and olanzapine87 or quetiapine,88 although 
the very small subject numbers (n = 7–10 subjects on active 
medication) suggest that neither trial was adequately powered 
statistically.
Other agents
Negative RCT outcomes have been reported for buspirone, 
a serotonin 1A partial agonist,89 and for atenolol, a beta-
adrenoceptor antagonist.89
Summary of medication response
Placebo-controlled RCT have been reported for seven drug 
classes in social phobia. Figure 5 shows the comparative OR 
Study
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Figure 4 Odds ratios and 95% Ci for treatment response in randomized placebo-controlled trials for the A2D ligands pregabalin (P) and gabapentin (G).
Response based on CGi for all studies. Only the highest pregabalin doses are reported for Pande et al73 and Feltner et al.74
Abbreviations: A2D, alpha-2-delta; CI, confidence interval; M-H, Mantel-Haenszel odds ratio.
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Figure 5 Odds ratios and 95% CI for treatment response in randomized placebo-controlled trials for five drug classes.
Abbreviations: CI, confidence interval; SSRIs, selective serotonin reuptake inhibitors; SNRIs, serotonin-norepinephrine reuptake inhibitors; MAOIs, monoamine oxidase 
inhibitors; irrev, irreversible; RIMA, selective inhibitors of monoamine oxidase A; M-H, Mantel-Haenszel odds ratio.
for treatment response for pooled results from five of these 
classes (insufficient data were available to include antipsy-
chotic and benzodiazepine class data). The greatest treatment 
response was for the irreversible nonselective monoamine 
oxidase inhibitor, phenelzine. It should be noted that this 
estimate is heavily influenced by data from one study,50 and 
that relatively few patients were included in the four studies. 
Because of the risk of food and drug interactions, use of this 
class of drugs would not be first-line. The OR for reversible 
selective inhibitors of monoamine oxidase A is influenced by 
brofaromine data; brofaromine is not available to prescribe, 
and responses for moclobemide alone are more modest 
(OR 1.95; 95% CI 1.37–2.79). The other three drug classes 
have similar OR for treatment response, suggesting that dif-
ferences in safety and tolerability profiles might influence 
selection between drug classes. Efficacy of the alpha-2 delta 
ligand, pregabalin, has only been reported at the 600 mg dose 
but not at lower doses; this higher dose is associated with 
high rates of dizziness and sedation. By default, this leaves 
SSRIs and the SNRI, venlafaxine, as first-line medication 
options for treatment of social phobia.
Psychological treatment trials
Over 30 randomized trials of psychological treatments 
have been conducted.15,16 Collectively these indicate that 
psychological interventions are effective in the treatment 
of social phobia. A critical issue is, however, effective rela-
tive to what? There is great variability in the nature of the 
control arm in psychological trials. These may include wait-
list control, psychological placebo, drug, drug-placebo, or 
treatment as usual (which may or may not include drugs). 
Most studies have used wait-list control which is the least 
stringent test of effectiveness. Recent meta-analyses of psy-
chological   treatments have found fairly large effect sizes for 
psychological treatments compared with wait-list controls 
(Cohen’s d of 0.86), but smaller effect sizes (0.36–0.38) 
compared with placebo or treatment as usual.15,16
In addition to the question of whether psychological 
treatments are effective, a second question is which psy-
chological treatment is optimal. Most studies, especially the 
earlier ones, have investigated variants or components of 
cognitive behavior therapy (CBT). The two meta-analyses 
cited earlier15,16 conducted subgroup analyses to determine 
whether inclusion of specific components of CBT, such as 
exposure, cognitive restructuring, relaxation, and social 
skills training makes a difference to treatment effectiveness. 
Neither study found significant differences in effectiveness 
as a function of inclusion versus noninclusion of any of 
these treatment components, nor did they find differences 
according to whether treatment was delivered individually 
or in group format.
This might suggest that it does not matter which type 
of psychological treatment is used, but recent trials of CBT 
against other evidence-based psychological treatments sug-
gest otherwise. Koszycki et al90 randomized participants 
with DSM-IV diagnoses of generalized social phobia to 
either group CBT or mindfulness-based stress reduction. 
Both groups improved, but the improvement with CBT was 
significantly greater. Borge et al91 compared interpersonal 
therapy with CBT in a randomized trial conducted in a 
residential setting. Both treatments were equally effective, 
although the researchers noted that the CBT intervention 
was associated with less improvement compared with that 
reported by prior researchers. In a recent randomized con-
trolled trial, Stangier et al92 compared cognitive therapy with 
interpersonal psychotherapy. Both treatments were superior 
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to wait-list control, but cognitive therapy was significantly 
more effective, a difference that was maintained at one-year 
follow-up. On the basis of this small number of studies, CBT 
or some variant of it remains the psychological treatment 
of choice, but interpersonal therapy or mindfulness-based 
therapies may be useful alternatives for patients who do not 
respond to CBT. A further important consideration is whether 
treatment effects endure. A meta-analysis of nine RCT of 
variants of CBT found significant effects at post-treatment 
(Cohen’s d of 0.68 across all trials) that were maintained at 
follow-up, with no drop in effect size (0.76).16
The availability of psychological treatments such as 
CBT is often limited by funding or therapist constraints, 
so recent RCT that have found Internet CBT to be equally 
effective as the therapist-delivered version are a promising 
development.93,94 More research is required to determine 
whether Internet therapy can be as effective as the therapist-
delivered version for the full spectrum of social phobia sever-
ity and complexity (in terms of comorbidity).
Medication versus psychological 
treatment
There are relatively few trials incorporating direct compari-
sons of medication with psychological treatments in social 
phobia. On the basis of the two trials shown in Figure 6, 
there are no significant differences in effectiveness between 
SSRIs and psychological treatments. One additional trial of 
cognitive therapy versus fluoxetine,95 which could not be 
included in the meta-analysis because the outcome analysis 
did not include responder data, found a significantly greater 
effectiveness of cognitive therapy. The meta-analysis of four 
monoamine oxidase inhibitor trials (Figure 6) suggests that 
these drugs may be superior to psychological treatments, but 
this result is not statistically significant.
It is also important to consider how these treatments com-
pare over the longer term. Three studies95–97 have published 
follow-up data on outcomes after a treatment-free period. In 
all three trials, the psychological treatment showed greater 
maintenance of treatment gains or protection against relapse 
relative to the drug treatments.
Medication versus combined medication-
psychological treatment trials
There are five studies that have assessed treatment response in 
direct comparisons of medication with combined medication-
psychological treatments in social phobia (two SSRI 
studies,33,39 two monoamine oxidase inhibitor studies,98,99 
and one benzodiazepine study100 Figure 7). For response 
rates in the SSRI and monoamine oxidase inhibitor stud-
ies, there were nonsignificant trends in favor of combined 
medication-psychological treatments over medication alone. 
For the single benzodiazepine study, there was a statisti-
cally significant advantage in favor of combined treatment 
(Figure 7). It should be noted that all studies were relatively 
small in size and thus may not have been adequately powered 
statistically.
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Figure 6 Odds ratios and 95% Ci for treatment response in randomized placebo-controlled trials for drug versus psychotherapy comparisons.
Blomhoff et al39 used exposure therapy; all other trials used cognitive behavioral therapy as the psychotherapy intervention. Response based on Clinical Global Impression 
for all studies except social phobia subscale of the Fear Questionnaire108 for Gelernter et al,53 and the Social Anxiety Scale107 for Heimberg et al.52
Abbreviations: CI, confidence interval; SSRIs, selective serotonin reuptake inhibitors; MAOIs, monoamine oxidase inhibitors; M-H, Mantel-Haenszel odds ratio.
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Blomhoff et al39 used exposure therapy; Knijnik et al100 used psychodynamic group therapy; all other trials used cognitive behavioral therapy as the psychotherapy intervention. 
Response based on Clinical Global impression for all studies.
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Figure 8 Odds ratios and 95% Ci for treatment response in randomized placebo-controlled trials for psychological therapy compared with combined medication-psychological 
treatment. Blomhoff et al39 used exposure therapy; all other trials used cognitive behavioral therapy as the psychotherapy intervention. Response based on Clinical Global 
impression for all studies.
Abbreviations: CI, confidence interval; SSRI, selective serotonin reuptake inhibitor; MAOI, monoamine oxidase inhibitor; M-H, Mantel-Haenszel odds ratio.
Psychological versus combined 
medication-psychological treatment trials
There are four studies that have assessed treatment response 
in direct comparisons of psychological treatment with 
combined medication-psychological treatments in social 
phobia (two SSRI studies,33,39 two monoamine oxidase 
inhibitor studies98,99 Figure 8). For the pooled response 
rate in the SSRI studies, there was a nonsignificant trend 
in favor of combined medication-psychological treatments 
over psychological treatment alone. For the pooled response 
rate in the monoamine oxidase inhibitor studies, there 
was a significant trend in favour of combined medication-
psychological treatments over psychological treatment alone 
(Figure 8). It should be noted that all studies were relatively 
small in size and thus may not have been adequately powered 
statistically.
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Discussion
All social phobia treatment guidelines recommend some 
combination of medication and psychological treatment for 
optimal management of patients with social phobia.17,18 Our 
meta-analysis findings are not inconsistent with this, although 
significant advantages of combination therapies are only evi-
dent with some drug classes and from a fairly small number 
of studies. For medications, the best initial choices would be 
SNRIs and SSRIs. For patients who do not respond to ade-
quate doses/durations of dosing of either of these drug classes, 
monoamine oxidase inhibitors would be a relevant second-line 
choice. The older nonselective irreversible monoamine oxi-
dase inhibitor, phenelzine, is clearly more effective than the 
newer reversible selective agent, moclobemide, although its 
use is constrained by its well known food and drug interaction 
liabilities and side effect profile at higher doses. A number 
of other drug classes are commonly used for symptom relief 
in social phobia, and appear to be effective, although clinical 
trial data are limited. Benzodiazepine use should be limited to 
brief courses because of their dependence liability, relatively 
high levels of cognitive toxicity,102 and potential for interfer-
ing with psychological treatment.103 Low doses of quetiapine 
are also commonly used for anxiolysis,104,105 but the one RCT 
for this drug in social phobia was clearly underpowered to 
assess its effect.88 Given that all benzodiazepines and most 
antipsychotic drugs have now become genericized, there is 
no commercial rationale for additional RCT in this area, and 
therefore it is unlikely that additional data will be generated 
to clarify how best to use these drugs in social phobia. The 
alpha-2-delta ligand, pregabalin, appears to have anxiolytic 
response rates comparable with SSRIs and SNRIs, but at 
doses of 600 mg/day where sedation and other side effects 
are likely to be reported, so its use should be reserved for 
refractory patients at this time. Combination drug treatment 
appears to be commonly used,80,81 but is not supported by 
RCT. The issue of how to treat patients who fail to respond 
to initial treatment is unresolved. A recent clinical guidance 
suggests a switching strategy, presumably based on data from 
the STAR*D studies,106 but this is not supported by clinical 
trial data.
Of the psychotherapeutic approaches, CBT or some 
variant of it appears to be the most effective psychological 
treatment. It has the largest evidence base, and thus far it 
has emerged as superior in head-to-head comparisons with 
other recently developed, evidence-based treatments of 
mental disorders. CBT also appears to offer better protec-
tion from relapse at termination of treatment relative to drug 
treatments.
Limitations
Most treatment trials, particularly medication trials, only 
enroll a highly selected group of patients. Patients with 
comorbid disorders, such as current depression, alcohol 
misuse disorders, or suicidal ideation are usually excluded. 
As noted in the Introduction, comorbidity is the rule 
rather than the exception for patients with social phobia. 
Moreover, social phobia has a high degree of overlap with 
agoraphobia,101 and can be accompanied by fears of public 
transport, meaning that some of the most severely affected 
will not seek treatment. This has implications for the gener-
alizability of the findings reported here.
The effectiveness of combined treatments for social 
phobia highlights the problem that psychological treatments 
are not widely available in most countries, and social phobia 
is one of the most prevalent mental disorders, suggesting 
significant unmet need for the optimal treatment package for 
this debilitating disorder. This makes the emerging evidence 
of the efficacy of Internet-based CBT,94 at least for uncompli-
cated presentations, a potentially important new opportunity 
to maximize the availability of combined treatments.
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